QR код

Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance

Trastuzumab (T) and tyrosine kinase inhibitors (TKIs) are among the first-line treatments recommended for HER2-positive breast cancer. More recently, antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) have been authorized, and they represent the...

Повний опис

Збережено в:
Автори: Claudiu Morgovan, Carmen Maximiliana Dobrea, Anca Butuca, Anca Maria Arseniu, Adina Frum, Luca Liviu Rus, Adriana Aurelia Chis, Anca Maria Juncan, Felicia Gabriela Gligor, Cecilia Georgescu, Steliana Ghibu, Andreea Loredana Vonica-Tincu
Формат: Artigo
Мова:Inglês
Опубліковано: MDPI AG 2024-04-01
Серія:Biomedicines
Предмети:
trastuzumab emtansine
trastuzumab deruxtecan
antibody-drug conjugates
HER2-positive breast cancer
HER2-targeted therapy
adverse reactions
Онлайн доступ:https://www.mdpi.com/2227-9059/12/5/953
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси